

**DAFTAR PUSTAKA**

- Adorini L. 2011. Control of Adaptive Immunity by Vitamin D. In: Feldman D, Pike JW, & Adams J. 3rd Edition. Volume 1. *VITAMIN D*. London: Elsevier.
- Abogamal AF, Mahmoud E, Abdulhakiem S, Abdellatif S & Abdalaziz AF, 2014. Insulin resistance in patients with psoriatic arthritis. *Al Azhar Assiut Medcail Journal*, 12 (3) : 95-116
- Ambarus C, Yeremenko N, Tak PP, Baeten D. 2012. Pathogenesis of spondyloarthritis: autoimmune or autoinflammatory. *Current Opinion in Rheumatology*; 24(1):351-358.
- Aranow C. 2011. Vitamin D and the Immune System. *Journal Investigation Medicine*. 59(6): 881-886.
- Araujo EG, Finzel S & Englbrecht M. 2015. High incidence of disease recurrence after discontinuation of disease-modifying antirheumatic drug treatment in apatient with psoriatic arthritis in remission. *Annals of The Rheumatic Disease*, 27: 118-126.
- Arnson Y, Amital H & Shoenfeld (2007) Vitamin D and autoimmunity: new aetiological and therapeutic considerations. *Annals of The Rheumatic Disease*, 66: 1137-1142.
- Arumugam R & McHugh NJ, 2012. Mortality and Causes of Death in Psoriatic Arthritis. *The Journal of Rheumatology*, 12 (89): 32-35.
- Aletaha D, Alasti F & Smolen JS. 2016. Disease activity states of the DAPSA, a psoriatic arthritis specific instrument, are valid against functional status and structural progression. *Annals of The Rheumatic Disease*, 716: 418-42.
- Asahina A, Umezawa Y, Yanaba K, Nakagawa H. 2015. Serum C-reactive protein levels in Japanese patients with psoriasis and psoriatic arthritis: Long-term differential effects of biologics. *J of Dermatol*, 42:1-6.
- Barnas JL & Ritchlin CT.2015. Etiology and Pathogenesis of Psoriatic Arthritis. *Rheumatic Disease Clinics North America*; 41: 643–663
- Beake F, Takiishi T, Korf H, Gysemans C, Mathieu C. 2010. Vitamin D: modulator of the immune system. *Current Opinion in Pharmacology*, 10(4): 482-496.
- Bouillon R, Carmeliet G, Verlinden L, Verstuyf A, Luderer HF, Lieben L, Mathieu C, Demav M. 2008. Vitamin D and Human Health: Lessons from Vitamin D Receptor Null Mice. *Endocr Rev*, 29(6): 726–776.

- Braun-Moscovici Y, Toledano K, Markovits D, Rozin A, Nahir AM, Balbir-Gurman A. 2009. Vitamin D level: is it related to disease activity in inflammatory joint disease?. *Rheumatol Int*, 31(4): 493–499.
- Brookbank JE, Stein M & Shentag CT, 2005. Dactylitis in psoriatic arthritis: a marker for disease severity. *Annals of The Rheumatic Disease*, 64: 188-190.
- Chailurkit LO Aekplakorn W, Ongphiphadhanakul B. 2011. Regional variation and determinants of vitamin D status in sunshine-abundant Thailand. , 10;11:853.
- Chen S, Sims GP, Chen XX, Gu YY, Chen S, Lipsky PE. 2007. Modulatory Effects of 1,25-Dihydroxyvitamin D3 on Human B cell Differentiation. *The Journal of Immunology*. 179: 1634-1647.
- Christakos S, Dhawan P, Verstuyf A, Verlinden L, and Carmeliet (2016) Vitamin D: Metabolism, Molecular Mechanism of Action, and Pleiotropic Effects. *Physiology Reviews*, 96: 365-408.
- Colbert R, Monica L, Gerlinde L & Dawan P, 2011. HLA-B27 misfolding and spodyloarthropathies. *Prion*, 3 (1): 15-26.
- Coates LC & Helliwell PS, 2008. Validation of minimal disease activity criteria for psoriatic arthritis using interventional trial data. *Arthritis Care & Research*, 62: 965-969.
- Chikanza IC & Grossman AB. 1998. Hypothalamic-pituitary-mediated immuno modulation: arginine vasopressin is a neuroendocrine immune mediator. *British Journal Rheumatology*, 37 :131-136.
- Chimenti MS, Triggianese P, Conigliaro P, Tonelli M, Gigliucci G, Novelli L, Teoli M & Perricone R, 2017. 2-year observational study on treatment targets in psoriatic arthritis patients treated with TNF inhibitors. *Clinical of Rheumatology*, 4:1-8
- Ciccia F, Bombardieri M, Principato A, Giardina A, Tripodo C, Porcasi R, Peralta S, Franco V, Giardina E, Craxi A, Pitzalis C, Triolo G. 2009. Overexpression of interleukin-23, but not interleukin-17, as an immunologic signature of subclinical intestinal inflammation in ankylosing spondylitis. *Arthritis and Rheumatology*; 60(4):955-65.
- Dankers W, Colin E, Hamburg, Lubberts E. 2017. Vitamin D in autoimmunity: molecular mechanisms and therapeutic potential. *Frontiers in Immunology*, 7: 697.
- Dangond CV, Villarino MR, Sancho J, Bernabeu EV, Pascual EV, Rodriguez JO, Garcia DY, Espi GA, Ferrer AM. 2015. Vitamin D Deficiency in Patient with Psoriatic Arthritis and Its Role in Disease Activity. *Annals of the Rheumatic Disease*. 74(suppl 2): 760.

- Dawson-Hughes B, Harris SS, Ceglia L, Palermo NJ. 2014. Effect of Supplemental Vitamin D and Calcium on Serum Sclerostin Levels. *European Journal of Endocrinology*; 170(4):645-50.
- Dikbass O, Tosun M, Bes C, Tonuk SB, Yilmaz O, Aksehirli & Soy M, 2016. Serum levels of visfatin, resistin and adiponectin in patients with psoriatic arthritis and associations with disease severity. *International Journal of Rheumatic Diseases*, 19: 672-677.
- Essouma M and Noubiap JJN. 2017. Are systematic screening for vitamin D deficiency and vitamin D supplementation currently feasible for Ankylosing Spondylitis patients. *Hindawi International Journal of Inflammation*; 17: 1-10.
- Eder L, Chandran V & Gladman DD, 2012. Gender-related differences in patients with Psoriatic Arthritis. *International Journal of Clinical Rheumatology*, 7 (6): 641-649.
- Fearon U & Veale DJ. 2001. Pathogenesis of psoriatic arthritis. *Clinical and Experimental Dermatology*, 26 : 333-337.
- Ferguson EG & Coates LC. 2014. Optimisation of rheumatology indices: dactylitis and enthesitis in psoriatic arthritis. *Clinical and Experimental Rheumatology*, 32 (55): 113-117.
- Feltkamp EW, Mardjuadi A, Huang F & Chou CT, 2001. Spondyloarthropathies in eastern Asia. *Current Opinion in Rheumatology*, 13 (4): 285-290.
- Fitzgerald and Elmamoun M. 2017. Psoriatic Arthritis, in G Firestein, RC Budd, SE Gabriel, IB McInnes, JR O'dell(ed.), Kelley & Firestein's *Textbook of Rheumatology*, 11th edn, Elsevier, Philadelphia, pp. 1285-1308.
- FitzGerald O & Winchester R. 2019. Psoriatic arthritis: from pathogenesis to therapy. *Arthritis Research and Therapy*; 11: 214-223.
- Gladman DD, Ng Tung HE, Schentag CT. 2001. Remission in psoriatic arthritis. *The Journal of Rheumatology*; 28: 1045–1048.
- Gudbjornsson B, Ejstrup L, Gran JT. 2013. Psoriatic arthritis mutilans (PAM) in the Nordic countries: demographics and disease status. The Nordic PAM study. *Scandinavian Journal of Rheumatology*. 42: 373–378.
- Gallieni M, Cozzolino M, Fallabrino G, PashoS, Olivi L, Brancaccio D. 2009. Vitamin D: Physiology and pathophysiology. *The International Journal of Artificial Organs*; 32:87-94.
- Garfinkel RJ, Dilisio MF, Agrawal DK (2017) Vitamin D and its effects on articular cartilage and osteoarthritis. *The Orthopedic Journal of Sports Medicine*.5(6): 1-8.

- Gladman DD, Hing E, Schentag CT. 2001. Remission in Psoriatic Arthritis. *The Journal of Rheumatology*; 28:1045–8.
- Golden JB, McCormick TS, Ward NL. 2013. IL-17 in psoriasis: Implications for therapy and cardiovascular co-morbidities. *Cytokine*; 62(2):195-201.
- Gottlieb A, Menter A, Mendelsohn A, Shen Y, Guzzo C, Li S, Fretzin S, Kunynetz R, Kavanaugh A. 2009. Ustekinumab, a human interleukin 12/23 monoclonal antibody, for psoriatic arthritis: randomised, double-blind, placebo-controlled, crossover trial. *Lancet*; 373(9664).
- Grazio, S., Grubišić, F., Kavanagh, H. S., Naglić, Đ. B., Anić, B., Bakula, M, Cvijetić, S. (2015). Vitamin D Serum Level, Disease Activity and Functional Ability in Different Rheumatic Patients. *AJMS*, 349(1), 46–49.
- Guillot X, Prati C and Wendling D. 2014. Vitamin D and Spondyloarthritis. *Expert Review of Clinical Immunology*, 2014: 1-9.
- Hadidi HE, Grace BDM, Gheita T & Shaker O, 2008. Involvement of IL-23 in psoriasis and psoriatic arthritis patients; possible role in pathogenesis. *Journal Egypt of Dermatology Society*, 5(2): 77.
- Healy PJ, groves C & Chandramohan M, 2008. MRI changes in psoriatic dactylitis-extent of pathology, relationship to tenderness and correlation with clinical indices. *Rheumatology*, 47 (1): 92-95.
- Helliwell PS & Kavanaugh A, 2013. The development of candidate composite disease activity and responder indices for psoriatic arthritis (GRACE project). *Annals of The Rheumatic Disease*, 72 (6): 986-991.
- Helliwell PS, 2015. Assessment of disease activity in psoriatic arthritis. *Clinical and Experimental Rheumatology*, 33(93): 44-47.
- Hermann E, Yu DT, Zum Buschenfelde K-HM, Fleischer B. 1993. HLA-B27-restricted CD8 T cells derived from synovial fluids of patients with reactive arthritis and ankylosing spondylitis. *Lancet*; 342(1):646-650
- Hewison M, 2012. Vitamin D and immune function: an overview. *The Proceeding of the Nutrition Society*; 71(1): 50-61.
- Holick MF, 2003. Vitamin D Deficiency: What a Pain It Is. *Mayo Clinic Proceedings*, 78(12): 1457-1459.
- Holick MF, Binkley NC, Bischoff-Ferrari HA, Gordon CM, Hanley DA, Heaney R. 2011. Evaluation, treatment, and prevention of vitamin D deficiency: An endocrine society clinical practice guideline. *The Journal of Clinical Endocrinology & Metabolism*; 96(7):1911-30.
- Holick MF, 2007. Optimal vitamin D status for the prevention and treatment of osteoporosis. *Drugs Aging*, 24(12):1017-29.

- Hmamouchi I, Allali F, Hamdoui BE, Amine H, Rostom S, 2013. The relation between disease activity, vitamin D levels and bone mineral density in men patients with ankylosing spondylitis. *Rheumatology Reports*. 5(3): 7-12.
- Ho-Pham LT, Nguyen ND, Lai TQ, Elsmann JA, Nguyen TV. 2011. Vitamin D status and parathyroid hormone in a urban population in Vietnam. *Osteoporos Int* (2011), 22:241–248.
- Ibrahim AM, Itamimy HM, Rayan MM, Abdul-Hamied HI. 2013. Measurement of Vitamin D and Its Relation to Psoriatic Arthritis. *AAMJ*, 11(2): 292-304.
- Jadon DR, Shaddick G, Tillett W. 2015. Psoriatic arthritis mutilans: characteristics and natural radiographic history. *Journal of Rheumatology*; 42(7):1169–76.
- Jung J, Choi M-S. 2014. Obesity and Its Metabolic Complications: The Role of Adipokines and the Relationship between Obesity, Inflammation, Insulin Resistance, Dyslipidemia and Nonalcoholic Fatty Liver Disease. *International Journal of Molecular Sciences*; 15(4):6182-6223.
- Kane D, Stafford L & Bresnihan B. 2003. Aprospective, clinical and radiological study of early psoriatic arthritis: an early synovitis clinic experience. *Rheumatology*, 12: 1460-1468.
- Kean WF, Buchanan WW. 2005. The use of NSAIDs in rheumatic disorders 2005: a global perspective. *Inflammopharmacology.*, 13(4):343-70.
- Lange U, jung O, Teichmann J, Neeck G (2001) Relationship between disease activity and serum levels of vitamin D metabolites and parathyroid hormone in ankylosing spondylitis. *Osteoporosis International*. 12: 1031-1035.
- Lai TL, Yim CW, Leung MC, Wong PY & Ng WL, 2018. Clinical characteristics and comorbidities of psoriatic arthritis (PsA) in Hong Kong. *Hong Kong Bulletin on Rheumatic Diseases*, 2: 47-55.
- Lee S, Mendelson M & Sarnes E, 2010. The Burden of Psoriatic Arthritis. *Pharmacy and Therapeutic Journal*, 35(12): 680-689.
- Littlewood S & MacPhie E. 2014. Evaluation of a Psoriatic Arthritis Response Criteria Standardization Training Session for Clinicians. *Rheumatology*, 53 (1): 447-553.
- Leung YY, Tam LS, Li EK. 2011. The perspective on psoriatic arthritis in Asia. *Curr Rheumatol Rep*, 13(4):369-75.
- Mathieu S, Gossec L, Dougados M, Soubrier M. 2011. Cardiovascular profile in ankylosing spondylitis: a systematic review and meta-analysis. *Arthritis Care & Research*; 63(4):557-563.

- Mear J, Schreiber K, Munz C, Zhu X, Stevanovic S, Rammensee H-G. 1999. Misfolding of HLA-B27 as a result of its B pocket suggests a novel mechanism for its role in susceptibility to spondyloarthropathies. *Journal of Immunology Research*; 163(20):6665-70.
- Mease PJ, Kavanaugh A, Coates LC, McInnes IB, Hojnik M, Zhang Y, Anderson JK, Dorr AP & Gladman DD, 2017. Prediction and benefits of minimal disease activity in patients with psoriatic arthritis and active skin disease in the ADEPT trial. *Rheumatic & Musculoskeletal Disease*, 3: 1-10
- Moghaddassi M, Shahram F, Chams-Davatchi C, Najafizadeh S & Davatchi F, 2009. Different aspects of psoriasis: analysis of 150 Iranian patients *Archive of Iranian Medicine*, 12 : 279-83.
- Nograles KE, Brasington RD & Bowcock AM, 2009. New insight into the pathogenesis and genetics of psoriatic arthritis. *Nature Clinical Practice Rheumatology*, 5 (2): 83-91.
- Ohara Y, Kishimoto M, Takizawa N, Yoshida K, Okada M, Eto H, Deshpande GA, Ritchlin CT, Tanaka A, Higashiyama M, Matsui K, Tsuji S. 2015. Prevalence and Clinical Characteristics of Psoriatic Arthritis in Japan. *J Rheum*, 42(8):1-5.
- Orgaz-Molina J, Buendía-Eisman A, Arrabal-Polo MA, Ruiz JC, Arias-Santiago S. 2012. Deficiency of serum concentration of 25-hydroxyvitamin D in psoriatic patients: A case-control study. *J Am Acad Dermatol*, 67(5), 931–938.
- Öten E, Başkan B, Sivas F, Bodur H. 2017. Relation Between Osteoporosis and Vitamin D Levels and Disease Activity in Psoriatic Arthritis. *Erciyes Medical Journal*; 39(3): 94-100.
- Paine A & Ritchlin C. 2016. Bone remodeling in psoriasis and psoriatic arthritis: an update. *Current Opinion in Rheumatology*; 28(1): 66 –75.
- Plotnikoff GA, & Quigley JM. 2003. Prevalence of Severe Hypovitaminosis D in Patients With Persistent, Nonspecific Musculoskeletal Pain. *Mayo Clinic Proceedings*, 78(12): 1463–1470.
- Patel S, Farragher T, Berry J, Bunn D, Silman A, Symmons D. 2007. Association between serum vitamin D metabolite levels and disease activity in patients with early inflammatory polyarthritis. *Arthritis Rheum*. 2007, 56(7):2143-9
- Petersen AMW & Pedersen BK, 2005. The anti-inflammatory effect of exercise. *Journal of Applied Physiology*, 98: 1154–1162.
- Petho Z, Kulesar-Jakab E, Kalina E, Balogh A, Puszai A, Gulyas K, Horvath A, Szakanez Z, Bhattoa HP. 2014. Vitamin D status in men with psoriatic arthritis: a case-control study. *Osteoporosis Int*, 26(7): 1-6.

- Punzi L, 1999. Clinical and laboratory manifestations of elderly onset psoriatic arthritis: A comparison with younger onset disease. *Annals of the Rheumatic Diseases*, 58:226–229.
- Pokhai GG, Bandagi S and Abrudescu A. 2014. Vitamin D levels in Ankylosing Spondylitis: Does deficiency correspond to disease activity?. *Revista Brasileira de Reumatologia*. 54(4): 330-334.
- Prietl B, Treiber G, Pieber TR, Amrein K. 2013. Vitamin D and Immune Function. *Nutrients*, 5: 2502-2521.
- Queiro R, Tejon P, Coto P, Alonso S, Alperi M, Sarasqueta C, Gonzales S, Morra JM, Larrea CL & Ballina J, 2013. Clinical Difference between Men and Women with Psoriatic Arthritis: Relevance of the Analysis of Genes and polymorphisms in the Major Histocompatibility Complex region and of the Age at Onset of psoriasis. *Clinical and Developmental Immunology*, 13: 1-7.
- Raychaudhuri SP, Wilken R, Sukhov AC, Raychaudhuri SK, Maverakis E (2017). Management of psoriatic arthritis: Early diagnosis, monitoring of disease severity and cutting edge therapies. *J Autoimmun.*, 76:21-37.
- Reynolds JA and Bruce IA. 2016. Vitamin D treatment for connective tissue diseases: hope beyond the hype?. *Rheumatology*, 270: 1-9.
- Radke MA, Beikert FC & Augustin M. 2013. Nail psoriasis-a treatment challenge. *Journal Deutsche Dermatologische Gessellschaft.*, 11(3): 203-219.
- Reveille JD, Hirsch R, Dillon CF, Carroll MD & Weisman MH, 2009. The Prevalence of HLA-B\*27 in the US: Data From the US National Health and Nutrition Examination Survey. *Arthritis of Rheumatology*, 64 (5): 1407–1411.
- Ritchlin CT, Colbert RA & Gladman DD, 2017. Psoriatic Arthritis. *The New England Journal of Medicine*, 376 (10): 957-970.
- Sağ MS, Sağ S, Tekeoğlu İ, Solak B, Kamanlı A, Nas K, Harman H, Kantar M. 2018. Comparison of 25-hidroksi Vitamin D serum concentrations in patients with psoriasis and psoriatic arthritis. *J Back Musculoskelet Rehabil*. 31(1): 37-43.
- Salaffi F, Ciapetti A, Carotti M, Gasparini S & Gutierrez M, 2014. Disease Activity in Psoriatic Arthritis: Comparison of the Discriminative Capacity and Construct Validity of Six Composite Indices in a Real World. *Biomed Research International*, 2014: 1-12.
- Sarzi-Puttini P, Santandrea S, Boccassini L, Panni B, Caruso I. 2001. The role of NSAIDs in psoriatic arthritis: evidence from a controlled study with nimesulide. *Clin Exp Rheumatol.*, 19(22): 17-20.

- Shiber MD & Molad MDY, 2016. Elevated c-reactive protein level predicts earlier treatment with tumor necrosis factor-alpha inhibitors in Psoriatic Arthritis. *Israel medical association journal (IMAJ)*, 18: 279-282.
- Sibley CH, 2016. Autoinflammation and HLA-B27: more than antigen. *Ocular Immunology and Inflammation*, 24 (4): 460-469.
- Siegel EL, Orbai AM & Ritchlin CT, 2015. Targeting extra-articular manifestations in PsA: a closer look at enthesitis and dactylitis. *Current Opinion of Rheumatology*, 27 (2): 111-117.
- Smith JA and Colbert RA (2014) The IL-23/IL-17 Axis in Spondyloarthritis Pathogenesis: Th17 and Beyond. *Arthritis and Rheumatology*, 66(2): 231-241
- Suzuki E, Mellins ED, Gershwin ME, Nestle FO & Adamopoulos IE, 2014. The IL-23/IL-17 axis in psoriatic arthritis. *Autoimmunity Reviews*, 1535: 1-7.
- Schoels MM, Aletaha D, Alasti F & Smolen JS, 2016. Disease activity in psoriatic arthritis (PsA): defining remission and treatment success using the DAPSA score. *Annals of Rheumatic Diseases*, 75: 811-818.
- Smolen JS, Schoels M, Aletaha D. 2015. Disease activity and response assessment in psoriatic arthritis using the Disease Activity index for Psoriatic Arthritis (DAPSA). A brief review. *Clinical and Experimental Rheumatology*; 33(93): S48-S50.
- Tam LS, Leung YY & Li EK, 2009. Psoriatic arthritis in Asia. *Rheumatology*, 48: 1473-7.
- Taurog J, Dorris M, Satumtira N, Tran T, Sharma R, R D, Van Den Brandt J, Reichardt H. 2009. Spondylarthritis in HLA-B27/human beta2-microglobulin-transgenic rats is not prevented by lack of CD8. *Arthritis and Rheumatology*; 60(7):1977-84.
- Tillet W, 2014. Work Disability in Psoriatic Arthritis. *Rheumatology*, 5: 157-162
- Tillet W, Shaddick G, Askari A. 2015. Factors influencing work disability in psoriatic arthritis: first result from a large UK multicentre study. *Rheumatology*, 54: 157-162.
- Touma Z, Eder L, Zisman D, Feld J, Chandran V, Rosen CF, Shen H, Cook RJ, Gladman DD. 2011. Seasonal Variation in Vitamin D Levels in Psoriatic Arthritis Patients From Different Latitudes and Its Association With Clinical Outcomes. *Arthritis Care and Research*; 63 (10): 1440–1447
- Veale DJ & Fitzgerald O. 2002. Psoriatic arthritis-Pathogenesis and epidemiology. *Clinical Experience in Rheumatology*, 20 (28): 27-33.



- Velea DJ. 2013. Psoriatic arthritis: recent progress in pathophysiology and drug development. *Arthritis Research and Therapy* ;15: 224-230.
- Vijayakumaran N, Asokan N, Krishnan J & Narayanan B, 2016. Clinical and radiological findings in psoriatic arthritis: A hospital-based cross-sectional study. *Muller Journal of Medical Sciences and Research*, 7(2) : 91-95.
- Verma I, Syngle A & Krishan P, 2016. Endothelial progenitor cell biology in psoriatic arthritis patients in the absence of traditional cardiovascular risk. *Indian Journal of Rheumatology*, 11: 14-20.
- Wei R & Christakos S, 2015. Mechanism underlying the regulation of innate and adaptive immunity by Vitamin D; *Nutrients*. 7(10): 8251-8260
- Wei JC, Shi LH, Huang JY, Wu XF, Wu R, Chiou JY. 2018. Epidemiology and Medication Pattern Change of Psoriatic Diseases in Taiwan from 2000 to 2013: A Nationwide, Population-based Cohort Study. *J Rheumatol*, 45(3):385-392.
- Williams JP & Meyers JA. Immune-mediated inflammatory disorders (I.M.I.D.s): The economic and clinical costs. *The American Journal of Management Care*, 8: 664–681.
- Yang Q, Qu L, Tian H, Hu Y, Peng J, Yu X, Yu C, Pei Z, Wang G, Shi B. 2011. Prevalence and Characteristics of Psoriatic Arthritis in Chinese Patients with Psoriasis. *JEADV* , 25; 1409–1414.
- Zaffarana C, Gallino Yanzi J, Cerda OL, Landi M, Schneeberger E & Citera G, 2016. Prevalence of Obesity in Patients with Psoriatic Arthritis and Its Impact on the Severity of the Disease. *Arthritis Rheumatology*, 68(10): 27-68.
- Zhou Q, Qin S, Zhang Z, Zhon L, Pen Z (2017) 1,25(OH)2D3 induces regulatory T cell differentiation by influencing the VDR/PLC-  $\gamma$ 1/TGF- $\beta$ 1/pathway. *Molecular Biology*. 91: 156-164.